Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.5175
+0.0771 (17.51%)
At close: Aug 12, 2025, 4:00 PM
0.5290
+0.0115 (2.22%)
Pre-market: Aug 13, 2025, 5:01 AM EDT
Acelyrin Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$446,481
Profits / Employee
-$345,940
Market Cap
156.13M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 183 | -222 | -54.81% |
Dec 31, 2023 | 405 | -73 | -15.27% |
Dec 31, 2022 | 478 | 47 | 10.90% |
Dec 31, 2021 | 431 | 18 | 4.36% |
Dec 31, 2020 | 413 | 59 | 16.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SGMO News
- 4 days ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire
- 12 days ago - Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call - GlobeNewsWire
- 7 weeks ago - Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
- 3 months ago - Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - Business Wire
- 3 months ago - Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Business Wire
- 3 months ago - Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - Business Wire